Multivariate analysis comparing MSD with URD with mmRD
| Outcome . | mmRD vs MSD . | URD vs MSD . | URD vs mmRD . | |||
|---|---|---|---|---|---|---|
| RR (95%CI) . | P . | RR (95%CI) . | P . | RR (95%CI) . | P . | |
| Acute GVHD 2-4* | 2.70 (2.13-3.42) | < .001 | 1.76 (1.42-2.18) | < .001 | 0.65 (0.49-0.86) | .003 |
| Acute GVHD 3-4† | 3.41 (2.38-4.89) | < .001 | 2.54 (1.78-3.64) | < .001 | 0.75 (0.49-1.14) | .177 |
| Chronic GVHD‡ | 3.09 (2.24-4.27) | < .001 | 3.92 (3.00-5.13) | < .001 | 1.27 (0.88-1.82) | .198 |
| TRM§ | 3.01 (2.10-4.33) | < .001 | 3.48 (2.54-4.77) | < .001 | 1.16 (0.77-1.64) | .739 |
| Relapse‖ | 0.90 (0.65-1.24) | .516 | 0.98 (0.76-1.27) | .874 | 1.09 (0.74-1.60) | .661 |
| Disease-free survival¶ | 1.38 (1.09-1.75) | .008 | 1.41 (1.16-1.70) | < .001 | 1.02 (0.77-1.35) | .904 |
| Overall survival# | 1.55 (1.21-1.98) | < .001 | 1.46 (1.18-1.80) | < .001 | 0.94 (0.71-1.26) | .686 |
| Outcome . | mmRD vs MSD . | URD vs MSD . | URD vs mmRD . | |||
|---|---|---|---|---|---|---|
| RR (95%CI) . | P . | RR (95%CI) . | P . | RR (95%CI) . | P . | |
| Acute GVHD 2-4* | 2.70 (2.13-3.42) | < .001 | 1.76 (1.42-2.18) | < .001 | 0.65 (0.49-0.86) | .003 |
| Acute GVHD 3-4† | 3.41 (2.38-4.89) | < .001 | 2.54 (1.78-3.64) | < .001 | 0.75 (0.49-1.14) | .177 |
| Chronic GVHD‡ | 3.09 (2.24-4.27) | < .001 | 3.92 (3.00-5.13) | < .001 | 1.27 (0.88-1.82) | .198 |
| TRM§ | 3.01 (2.10-4.33) | < .001 | 3.48 (2.54-4.77) | < .001 | 1.16 (0.77-1.64) | .739 |
| Relapse‖ | 0.90 (0.65-1.24) | .516 | 0.98 (0.76-1.27) | .874 | 1.09 (0.74-1.60) | .661 |
| Disease-free survival¶ | 1.38 (1.09-1.75) | .008 | 1.41 (1.16-1.70) | < .001 | 1.02 (0.77-1.35) | .904 |
| Overall survival# | 1.55 (1.21-1.98) | < .001 | 1.46 (1.18-1.80) | < .001 | 0.94 (0.71-1.26) | .686 |
MSD indicates matched sibling donor transplant; URD, 8/8 matched unrelated donor transplant; mmRD, 1-antigen mismatch related donor/phenotypically matched donor transplant; RR, relative risk; CI, confidence interval; GVHD, graft-versus-host disease; and TRM, treatment-related mortality.
Adjusted for total body irradiation use and stratified by GVHD prophylaxis.
Adjusted for year of transplantation and stratified by GVHD prophylaxis.
Adjusted for donor-recipient sex match, performance score, recipient age at transplantation, GVHD prophylaxis, and antithymocyte globulin use.
Adjusted for recipient age at transplantation, performance score, disease, donor-recipient sex match, and year of transplantation.
Adjusted for total body irradiation use in conditioning and year of transplantation and stratified by performance score, disease, disease status, and time from diagnosis to transplantation.
Adjusted for donor-recipient cytomegalovirus match and recipient age at transplantation and stratified by disease and disease status.
Adjusted for disease, disease status, recipient age at transplantation, and stratified by performance score, use of antithymocyte globulin in conditioning, and years of transplantation.